Given the comments of Solagran management - that Ropren approval is "99% certain," we are all aware that approval has been priced into this stock. There is only one question that bugs me: how far will it fall if the Russian authorities request more data?
Probably not too far, but then it will be either time to partner with big pharma, or time for a capital raising.
Either one will result in further dilution of an already hefty 300 million market cap.
Just a warning not to trade this one. There is no upside to Ropren approval, so this is best digested from the sidelines. A capital raising will come at a significant discount to the market price.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.020(8.89%) |
Mkt cap ! $14.20M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 25.5¢ | 23.0¢ | $168.5K | 699.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 47000 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 9326 | 1 |
View Market Depth
| Last trade - 15.55pm 25/07/2025 (20 minute delay) ? |
| SLA (ASX) Chart |